ADMA:NSC-ADMA Biologics Inc (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 9.6

Change

+0.19 (+2.02)%

Market Cap

USD 0.07B

Volume

3.36M

Analyst Target

USD 9.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ADMA Biologics Inc is a biopharmaceutical company. The Company develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing ADMA

FDLS Northern Lights Fund Trus.. 1.45 % 0.00 %

-0.49 (-1.63%)

USD 0.09B
IWC iShares Micro-Cap ETF 0.57 % 0.60 %

-2.22 (-1.63%)

USD 0.82B
ISMD Inspire Small/Mid Cap Imp.. 0.33 % 0.62 %

-0.36 (-1.63%)

USD 0.19B
DWAS Invesco DWA SmallCap Mome.. 0.00 % 0.60 %

-1.82 (-1.63%)

USD 0.93B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 112.39% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 112.39% 92% A 96% N/A
Trailing 12 Months  
Capital Gain 136.45% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.45% 94% A 96% N/A
Trailing 5 Years  
Capital Gain 104.26% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.26% 83% B 82% B
Average Annual (5 Year Horizon)  
Capital Gain 21.69% 74% C 80% B-
Dividend Return 21.69% 74% C 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 65.84% 43% F 25% F
Risk Adjusted Return 32.94% 85% B 67% D+
Market Capitalization 0.07B 89% A- 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 10.16 15% 11%
Price / Cash Flow Ratio 252.88 0% 1%
Price/Free Cash Flow Ratio 285.93 1% 1%
Management Effectiveness  
Return on Equity -2.43% 94% 56%
Return on Invested Capital 7.72% 87% 74%
Return on Assets 8.51% 98% 93%
Debt to Equity Ratio 96.59% 21% 24%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.